Phase 1 Supply: Feeding a Trial That Changes Its Mind Every Cohort

First-in-human supply is clinical logistics at its most paradoxical. The quantities are tiny — grams where later phases use kilos — yet the planning is hardest, because the one thing a dose-escalation study guarantees is that you don't know the doses. Each cohort's outcome decides the next cohort's strength; safety reviews insert pauses of unpredictable length; the formulation itself may still be evolving; and the drug arrives with the shortest shelf life it will ever have. Supplying Phase 1 well isn't about volume. It's about building maximum decision flexibility from minimum material.

Why is Phase 1 supply uniquely tricky?

Because uncertainty sits in every variable at once. Dose uncertainty: escalation designs (3+3, BOIN, and adaptive cousins) mean required strengths and quantities depend on live safety data; a scheme may skip, repeat, or insert dose levels, and expansion cohorts can multiply demand at a strength chosen late. Timing uncertainty: cohorts gate on safety review meetings whose outcomes and scheduling drift; supply must be ready for "proceed" without expiring during "pause." Product uncertainty: early formulations are often provisional — powder-in-bottle, extemporaneous compounding, simple capsules — with stability data measured in months and processes still maturing. Scale mismatch: batches are small and expensive per unit, made in facilities juggling many programs, so the reorder lead time is long exactly when the need is urgent.

How do you supply doses you haven't chosen yet?

By pushing the dose decision as late as possible in the physical chain — the Phase 1 version of postponement:

• Flexible dosage forms. Where science allows, formats that compose any dose from standard units: multiples of a low-strength capsule, weight-based dosing from a common vial concentration, or pharmacy-compounded solutions from bulk API. One inventory then serves every escalation decision.
• Late-stage kit assembly. Hold bulk or semi-finished stock centrally; label and assemble per cohort once the dose is declared. This trades a short assembly turnaround for immunity to dose surprises.
• Cohort-triggered supply rhythm. Tie packaging and release milestones to the escalation calendar — a defined turnaround from dose-decision to site-ready — and make that turnaround a designed, rehearsed number rather than a hope.
• Deliberate strength menus. If fixed strengths are unavoidable, choose denominations like currency: a small set of strengths that combine to cover the plausible dose range, rather than manufacturing each level bespoke.

How much drug should an early program actually make?

Less than fear suggests, more often than the first batch implies — the real answer is a campaign plan, not a number. Model the escalation scenarios (fastest, expected, slowest with repeats and expansions) against batch sizes, lead times, and the stability-limited usable window, and plan manufacture in waves that each cover the decisions visible from here. Over-making early is uniquely wasteful in Phase 1: the material is expensive, the shelf life short, and a formulation change can obsolete inventory overnight. Under-making stalls cohorts and burns the scarcest resource — momentum at the program's most-watched stage. The stability program deserves co-equal attention: every real-time data point extends the usable window, and early-phase supply plans should be built around when those extensions land.

What else deserves early-phase attention?

Three quieter fronts. Pharmacy partnership: Phase 1 units and their pharmacies do the last transformation — reconstitution, compounding, per-patient preparation — so manuals, training, and in-use stability data are supply deliverables, not afterthoughts. Accountability at micro-scale: with single patients on single doses, every vial is traceable and every deviation visible; the habits described in our reconciliation playbook start here, in miniature. The bridge to Phase 2: the end of escalation is the beginning of the next study's demand — decisions about formulation lock, batch scale-up, and comparator strategy made during Phase 1 determine whether Phase 2 starts on time. The best early-phase supply teams are already planning the study after this one.